Insulin, Physical Activity, and Caloric Intake in Postmenopausal Women: Breast Cancer Implications KIT is a target for imatinib mesylate (Gleevec; Novartis Pharma, Basel, Switzerland).
NEW YORK, March 18, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company, today announced breakthrough preclinical findings demonstrating the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback